VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+25.81%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$241M
AUM Growth
+$50.3M
(+26%)
Cap. Flow
+$11.6M
Cap. Flow
% of AUM
4.82%
Top 10 Holdings %
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17
Top Buys
| 1 |
Brookfield Renewable
BEPC
|
$1.83M |
| 2 |
Western Midstream Partners
WES
|
$1.11M |
| 3 |
Delek US
DK
|
$829K |
| 4 |
Viper Energy
VNOM
|
$789K |
| 5 |
Oneok
OKE
|
$751K |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$1.61M |
| 2 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$1.13M |
| 3 |
AIV
Aimco
AIV
|
$1.11M |
| 4 |
Telefônica Brasil
VIV
|
$1.01M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$988K |
Sector Composition
| 1 | Healthcare | 29.53% |
| 2 | Real Estate | 18.96% |
| 3 | Energy | 16.61% |
| 4 | Materials | 11.31% |
| 5 | Utilities | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Omeros
OMER
$284M
| $572K | 0.24% |
40,068
+132
| +0.3% | +$1.88K |
|
127
Ironwood Pharmaceuticals
IRWD
$188M
| $568K | 0.24% |
49,908
-14,038
| -22% | -$160K |
|
128
Theravance Biopharma
TBPH
$703M
| $568K | 0.24% |
31,966
+8,818
| +38% | +$157K |
|
129
PTC Therapeutics
PTCT
$4.55B
| $563K | 0.23% |
9,220
-2,643
| -22% | -$161K |
|
130
Nuveen Credit Strategies Income Fund
JQC
$746M
| $560K | 0.23% |
88,528
-780
| -0.9% | -$4.93K |
|
|
AMRS
131
DELISTED
Amyris Inc.
AMRS
| $560K | 0.23% |
90,634
+11,400
| +14% | +$70.4K |
|
|
VIE
132
DELISTED
Viela Bio, Inc. Common Stock
VIE
| $556K | 0.23% |
15,471
+8,887
| +135% | +$319K |
|
133
Ultragenyx Pharmaceutical
RARE
$3.07B
| $550K | 0.23% |
3,972
-4,615
| -54% | -$639K |
|
|
PRVL
134
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $544K | 0.23% |
23,601
+3,828
| +19% | +$88.2K |
|
135
Carlyle Secured Lending
CGBD
$1.01B
| $541K | 0.22% |
52,775
-31,819
| -38% | -$326K |
|
136
Harmony Biosciences
HRMY
$2.07B
| $539K | 0.22% |
+14,899
| New | +$539K |
|
137
Esperion Therapeutics
ESPR
$540M
| $535K | 0.22% |
20,576
+7,134
| +53% | +$185K |
|
138
Insmed
INSM
$30.7B
| $508K | 0.21% |
15,252
-6,244
| -29% | -$208K |
|
|
EPZM
139
DELISTED
Epizyme, Inc
EPZM
| $506K | 0.21% |
46,638
+12,952
| +38% | +$141K |
|
140
Prospect Capital
PSEC
$1.34B
| $498K | 0.21% |
92,036
-13,572
| -13% | -$73.4K |
|
141
Capital Southwest
CSWC
$1.28B
| $483K | 0.2% |
27,187
+12,388
| +84% | +$220K |
|
|
ICPT
142
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $466K | 0.19% |
18,849
+11,075
| +142% | +$274K |
|
143
BioNTech
BNTX
$27B
| $458K | 0.19% |
5,621
-742
| -12% | -$60.5K |
|
144
BlackRock TCP Capital
TCPC
$616M
| $443K | 0.18% |
39,441
-18,089
| -31% | -$203K |
|
|
HGEN
145
DELISTED
HUMANIGEN, INC.
HGEN
| $432K | 0.18% |
+24,667
| New | +$432K |
|
146
Arvinas
ARVN
$575M
| $429K | 0.18% |
5,053
-4,773
| -49% | -$405K |
|
147
New Mountain Finance
NMFC
$1.13B
| $428K | 0.18% |
37,694
-14,911
| -28% | -$169K |
|
148
Fidus Investment
FDUS
$757M
| $425K | 0.18% |
32,420
+11,336
| +54% | +$149K |
|
149
PennantPark Floating Rate Capital
PFLT
$1.02B
| $423K | 0.18% |
40,207
-22,553
| -36% | -$237K |
|
|
BGX
150
Blackstone Long-Short Credit Income Fund
BGX
$160M
| $422K | 0.18% |
31,430
-4,007
| -11% | -$53.8K |
|